Cargando…

Current treatment approaches in CML

Detalles Bibliográficos
Autores principales:	Castagnetti, Fausto, Gugliotta, Gabriele, Soverini, Simona, Baccarani, Michele, Rosti, Gianantonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Chronic myeloid leukemia - Section 6
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925665/ https://www.ncbi.nlm.nih.gov/pubmed/35309828 http://dx.doi.org/10.1097/HS9.0000000000000201

Ejemplares similares

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

NGS in CML - New standard diagnostic procedure?
por: Branford, Susan, et al.
Publicado: (2019)

IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia
por: Fiordi, Benedetta, et al.
Publicado: (2023)

CML-005: Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with a Donor and Recipient with SARS-CoV-2 Infection
por: Ali, Gadallah, et al.
Publicado: (2021)

CML-127 Results of a Vaccination Against COVID-19 by a Vector Based Vaccine Sputnik V in Patients With Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina, et al.
Publicado: (2022)

CML-384 Immunological Response to SARS-CoV-2 After Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients – A Prospective Study
por: Galvis, Marisol Miranda, et al.
Publicado: (2022)

TKI safety
por: Hjorth-Hansen, Henrik
Publicado: (2019)

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
por: Rea, Delphine, et al.
Publicado: (2020)

Chronic myeloid leukemia
por: Hantschel, Oliver
Publicado: (2019)

The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities
por: Patterson, Shaun David, et al.
Publicado: (2023)

Is There a Role for Dose Modification of TKI Therapy in CML?
por: Copland, M.
Publicado: (2019)

Treatment Recommendations for Chronic Myeloid Leukemia
por: Baccarani, Michele, et al.
Publicado: (2014)

Impact of the Covid-19 Pandemic on Quality of Life of Patients with CML
por: Wysoglad, Hubert, et al.
Publicado: (2021)

CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries
por: Matsuzaki, Mika, et al.
Publicado: (2023)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
por: Shanmuganathan, Naranie, et al.
Publicado: (2023)

The Role of Early Molecular Response in the Management of Chronic Phase CML
por: Harrington, Patrick, et al.
Publicado: (2017)

Treatment-Free Remission: the New Goal in CML Therapy
por: Atallah, Ehab, et al.
Publicado: (2021)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
por: Flynn, Kathryn E., et al.
Publicado: (2022)

RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
por: Zhang, Hualei, et al.
Publicado: (2022)

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
por: Dulucq, Stéphanie, et al.
Publicado: (2022)

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
por: Harrington, Patrick, et al.
Publicado: (2023)

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
por: Radich, Jerald P., et al.
Publicado: (2023)

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
por: Mancini, Manuela, et al.
Publicado: (2022)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia
por: Mancini, Manuela, et al.
Publicado: (2017)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)
por: Bonifacio, Massimiliano, et al.
Publicado: (2020)

Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence
por: Burchert, Andreas
Publicado: (2014)

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia
por: Claudiani, Simone, et al.
Publicado: (2020)

COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience
por: Pagnano, Katia B, et al.
Publicado: (2020)

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy
por: Luatti, Simona, et al.
Publicado: (2017)

Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia
por: Rabian, Florence, et al.
Publicado: (2019)

Acute myeloid leukemia
por: Haferlach, Torsten
Publicado: (2019)

AML-168: The Assessment of COVID-19 Evolution in Patients with Oncological Diseases Admitted in an Intensive Care Unit of One Romanian Center
por: Popov, Viola Maria, et al.
Publicado: (2021)

AML-145: Outcomes of Induction Therapy in Patients with Acute Myeloid Leukemia During Covid-19 Pandemic: A Retrospective Study from a Tertiary Care Cancer Centre
por: Iqbal, Asif, et al.
Publicado: (2021)

AML-355: Incidence and Severity of COVID-19 among Inpatients with Hematologic Malignancies
por: Wozniaki, Natalia, et al.
Publicado: (2021)

AML-075: Converting In-Person Research Procedures to a Virtual Platform During the COVID-19 Pandemic in Newly Diagnosed Acute Myeloid Leukemia Patients
por: Tinsley, Sara, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
por: Clark, Richard E.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gi4kdtr0festg1ir5kbc4fo6ek